Modifications of the Subchondral Bone in Aseptic Osteonecrosis of the Femoral Head (ONTF)
Study of Modifications of the Composition and Structure in the Aseptic Osteonecrosis of the Femoral Head and Etiopathogenic MRI Correlations
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lille, France, 59037
- Hospital Salengro CHU Lille
-
Lomme, France, 59462
- Hospital Group of the Catholic Institute of Lille
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria for experimental group:
- Men
- Patients aged from 25 to 70 years
- Patient with an aseptic osteonecrosis of the femoral head established by medical Imaging (CT-scan, MRI or radiography)
- FICAT stage 3 or 4
- osteonecrosis etiologies : alcohol, corticosteroid therapy, idiopathic
- Surgical indication of hip prosthesis determined
Inclusion Criteria for control group:
- Men
- Patients aged from 40 to 70 years
- Patient with a primitive coxarthrosis
- Surgical indication of hip prosthesis determined
Exclusion Criteria for the 2 groups:
- Other causes of osteonecrosis (coagulopathy, barotrauma, trauma)
- Prior fracture of the upper extremity of the femur
- Prior cancer and hematological malignancies with bone locations
- Prior debilitating bone diseases
- Patient refusal to participate in the study
- Patient who isn't affiliated to a social security regimen
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Osteonecrosis group
Patients with an aseptic osteonecrosis of the femoral head
|
|
|
Other: Control group
Patients with coxarthrosis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Osseous modifications responsible of osteonecrosis
Time Frame: through the study completion, an average of 18 months
|
through the study completion, an average of 18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total cross-sectional area
Time Frame: through the study completion, an average of 27 months
|
by using a contrast-enhanced nano-CT for the subchondral plate in necrotic zone, juxta-necrotic zone, remotely of the necrotic zone and cortical of the femoral collar
|
through the study completion, an average of 27 months
|
|
cortical bone area
Time Frame: through the study completion, an average of 27 months
|
by using a contrast-enhanced nano-CT for the subchondral plate in necrotic zone, juxta-necrotic zone, remotely of the necrotic zone and cortical of the femoral collar
|
through the study completion, an average of 27 months
|
|
cortical area fraction
Time Frame: through the study completion, an average of 27 months
|
by using a contrast-enhanced nano-CT for the subchondral plate in necrotic zone, juxta-necrotic zone, remotely of the necrotic zone and cortical of the femoral collar
|
through the study completion, an average of 27 months
|
|
cortical thickness
Time Frame: through the study completion, an average of 27 months
|
by using a contrast-enhanced nano-CT for the subchondral plate in necrotic zone, juxta-necrotic zone, remotely of the necrotic zone and cortical of the femoral collar
|
through the study completion, an average of 27 months
|
|
bone volume fraction
Time Frame: through the study completion, an average of 27 months
|
by using a contrast-enhanced nano-CT for the subchondral trabecular bone
|
through the study completion, an average of 27 months
|
|
trabecular number
Time Frame: through the study completion, an average of 27 months
|
by using a contrast-enhanced nano-CT for the subchondral trabecular bone
|
through the study completion, an average of 27 months
|
|
trabecular separation
Time Frame: through the study completion, an average of 27 months
|
by using a nano-CT for the subchondral trabecular bone
|
through the study completion, an average of 27 months
|
|
trabecular thickness
Time Frame: through the study completion, an average of 27 months
|
by using a contrast-enhanced nano-CT for the subchondral trabecular bone
|
through the study completion, an average of 27 months
|
|
Physico-chemical composition of the trabecular subchondral bone
Time Frame: through the study completion, an average of 27 months
|
mineralisation, carbonation, crystallinity, secondary structure of collagen, maturity of collagen, relative content of proteoglycans.
These measures will be done for the trabecular subchondral bone in necrotic zone, juxta-necrotic zone, remotely of the necrotic zone and in the cortical of the femoral collar
|
through the study completion, an average of 27 months
|
|
Existence and extent of edema
Time Frame: through the study completion, an average of 27 months
|
this measure will be done on the T2-weighted sequences with fat suppression
|
through the study completion, an average of 27 months
|
|
Perfusion MRI sequence
Time Frame: through the study completion, an average of 27 months
|
morphological aspect of the enhancement curve, semi-quantitative parameters (slope, area under the curve, time to peak) and pharmacokinetic parameters
|
through the study completion, an average of 27 months
|
|
Medullary fat fraction in T1-weighted DIXON method
Time Frame: through the study completion, an average of 27 months
|
border of osteosclerosis, identification of a necrotic zone, extent of this zone
|
through the study completion, an average of 27 months
|
|
Evaluation of osteocyte and adipocyte viability in hematoxylin-eosin-saffron (HES) staining
Time Frame: through the study completion, an average of 27 months
|
through the study completion, an average of 27 months
|
|
|
Number and ramifications of sub-chondral microvessels by immuno-labeling with CD21
Time Frame: through the study completion, an average of 27 months
|
through the study completion, an average of 27 months
|
|
|
Evaluation of the number of osteoclasts by TRAP (tartrate acid Phosphatase) staining
Time Frame: through the study completion, an average of 27 months
|
through the study completion, an average of 27 months
|
|
|
Mankin score for cartilage degradation by Safranin O staining
Time Frame: through the study completion, an average of 27 months
|
through the study completion, an average of 27 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Tristan Pascart, MD, Hospital Group of the Catholic Institute of Lille
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RC-P0044
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.